Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 36 studies | 41% ± 18% | |
smooth muscle cell | 14 studies | 23% ± 8% | |
connective tissue cell | 13 studies | 40% ± 22% | |
pericyte | 12 studies | 37% ± 11% | |
myofibroblast cell | 12 studies | 38% ± 11% | |
podocyte | 4 studies | 78% ± 12% | |
adventitial cell | 4 studies | 45% ± 8% | |
endothelial cell | 3 studies | 21% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 12977.82 | 459 / 459 | 94% | 137.33 | 1056 / 1118 |
thymus | 100% | 9799.89 | 652 / 653 | 88% | 243.87 | 530 / 605 |
prostate | 100% | 8471.20 | 244 / 245 | 88% | 44.09 | 440 / 502 |
lung | 99% | 8801.68 | 575 / 578 | 86% | 77.42 | 988 / 1155 |
ovary | 100% | 13923.66 | 180 / 180 | 79% | 98.22 | 339 / 430 |
intestine | 98% | 7935.28 | 948 / 966 | 71% | 55.90 | 375 / 527 |
bladder | 100% | 9152.05 | 21 / 21 | 67% | 59.09 | 338 / 504 |
esophagus | 95% | 5639.23 | 1369 / 1445 | 70% | 51.22 | 129 / 183 |
uterus | 100% | 17074.84 | 170 / 170 | 64% | 79.54 | 292 / 459 |
kidney | 96% | 4821.07 | 85 / 89 | 65% | 55.20 | 590 / 901 |
stomach | 75% | 4236.51 | 268 / 359 | 78% | 74.80 | 223 / 286 |
skin | 96% | 12383.01 | 1745 / 1809 | 46% | 34.61 | 218 / 472 |
pancreas | 13% | 386.64 | 42 / 328 | 93% | 169.50 | 166 / 178 |
adipose | 100% | 14212.34 | 1204 / 1204 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 48.23 | 1 / 1 |
blood vessel | 100% | 13679.14 | 1333 / 1335 | 0% | 0 | 0 / 0 |
spleen | 99% | 5817.96 | 238 / 241 | 0% | 0 | 0 / 0 |
adrenal gland | 65% | 2065.34 | 167 / 258 | 31% | 22.75 | 72 / 230 |
heart | 79% | 4029.98 | 682 / 861 | 0% | 0 | 0 / 0 |
brain | 16% | 373.86 | 419 / 2642 | 63% | 32.42 | 441 / 705 |
tonsil | 0% | 0 | 0 / 0 | 44% | 25.91 | 20 / 45 |
muscle | 35% | 1150.41 | 285 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 31% | 10.90 | 9 / 29 |
eye | 0% | 0 | 0 / 0 | 30% | 22.25 | 24 / 80 |
liver | 5% | 160.16 | 11 / 226 | 20% | 11.73 | 80 / 406 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0060857 | Biological process | establishment of glial blood-brain barrier |
GO_0007155 | Biological process | cell adhesion |
GO_0030154 | Biological process | cell differentiation |
GO_0060170 | Cellular component | ciliary membrane |
GO_0009986 | Cellular component | cell surface |
GO_0005788 | Cellular component | endoplasmic reticulum lumen |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005923 | Cellular component | bicellular tight junction |
GO_0005634 | Cellular component | nucleus |
GO_0005515 | Molecular function | protein binding |
GO_0003674 | Molecular function | molecular_function |
Gene name | MXRA8 |
Protein name | Matrix remodeling-associated protein 8 (Limitrin) |
Synonyms | |
Description | FUNCTION: Transmembrane protein which can modulate activity of various signaling pathways, probably via binding to integrin ITGAV:ITGB3 . Mediates heterophilic cell-cell interactions in vitro (By similarity). Inhibits osteoclastogenesis downstream of TNFSF11/RANKL and CSF1, where it may function by attenuating signaling via integrin ITGB3 and MAP kinase p38 (By similarity). Plays a role in cartilage formation where it promotes proliferation and maturation of growth plate chondrocytes (By similarity). Stimulates formation of primary cilia in chondrocytes (By similarity). Enhances expression of genes involved in the hedgehog signaling pathway in chondrocytes, including the hedgehog signaling molecule IHH; may also promote signaling via the PTHLH/PTHrP pathway (By similarity). Plays a role in angiogenesis where it suppresses migration of endothelial cells and also promotes their apoptosis . Inhibits VEGF-induced activation of AKT and p38 MAP kinase in endothelial cells . Also inhibits VTN (vitronectin)-mediated integrin ITGAV:ITGB3 signaling and activation of PTK2/FAK . May play a role in the maturation and maintenance of the blood-brain barrier (By similarity). .; FUNCTION: (Microbial infection) Contributes to arthritogenic alphavirus pathogenesis and acts as a receptor for these viruses. . |
Accessions | ENST00000309212.11 [Q9BRK3-1] ENST00000477278.3 [Q9BRK3-3] ENST00000342753.8 [Q9BRK3-4] Q9BRK3 ENST00000445648.5 [Q9BRK3-2] |